These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 21800009)

  • 1. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications.
    Spectre G; Arnetz L; Östenson CG; Brismar K; Li N; Hjemdahl P
    Thromb Haemost; 2011 Sep; 106(3):491-9. PubMed ID: 21800009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease.
    Capodanno D; Patel A; Dharmashankar K; Ferreiro JL; Ueno M; Kodali M; Tomasello SD; Capranzano P; Seecheran N; Darlington A; Tello-Montoliu A; Desai B; Bass TA; Angiolillo DJ
    Circ Cardiovasc Interv; 2011 Apr; 4(2):180-7. PubMed ID: 21386092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study.
    DiChiara J; Bliden KP; Tantry US; Hamed MS; Antonino MJ; Suarez TA; Bailon O; Singla A; Gurbel PA
    Diabetes; 2007 Dec; 56(12):3014-9. PubMed ID: 17848625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose- and time-dependent antiplatelet effects of aspirin.
    Perneby C; Wallén NH; Rooney C; Fitzgerald D; Hjemdahl P
    Thromb Haemost; 2006 Apr; 95(4):652-8. PubMed ID: 16601836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
    Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
    Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus.
    Santilli F; Davì G; Consoli A; Cipollone F; Mezzetti A; Falco A; Taraborelli T; Devangelio E; Ciabattoni G; Basili S; Patrono C
    J Am Coll Cardiol; 2006 Jan; 47(2):391-7. PubMed ID: 16412866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease.
    Dillinger JG; Drissa A; Sideris G; Bal dit Sollier C; Voicu S; Manzo Silberman S; Logeart D; Drouet L; Henry P
    Am Heart J; 2012 Oct; 164(4):600-606.e1. PubMed ID: 23067920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
    Markuszewski L; Rosiak M; Golanski J; Rysz J; Spychalska M; Watala C
    Basic Clin Pharmacol Toxicol; 2006 May; 98(5):503-9. PubMed ID: 16635110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet function one and three months after coronary bypass surgery in relation to once or twice daily dosing of acetylsalicylic acid.
    Ivert T; Dalén M; Ander C; Stålesen R; Näsman P; Lordkipanidzé M; Hjemdahl P
    Thromb Res; 2017 Jan; 149():64-69. PubMed ID: 27907814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of aspirin response by Multiplate whole blood aggregometry and light transmission aggregometry.
    Pedersen SB; Grove EL; Nielsen HL; Mortensen J; Kristensen SD; Hvas AM
    Platelets; 2009 Sep; 20(6):415-20. PubMed ID: 19658002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes.
    Christensen KH; Grove EL; Würtz M; Kristensen SD; Hvas AM
    Platelets; 2015; 26(3):230-5. PubMed ID: 24750015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.
    Angiolillo DJ; Bernardo E; Capodanno D; Vivas D; Sabaté M; Ferreiro JL; Ueno M; Jimenez-Quevedo P; Alfonso F; Bass TA; Macaya C; Fernandez-Ortiz A
    J Am Coll Cardiol; 2010 Mar; 55(11):1139-46. PubMed ID: 20223369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet function recovery after cessation of aspirin: preliminary study of volunteers and surgical patients.
    Zisman E; Erport A; Kohanovsky E; Ballagulah M; Cassel A; Quitt M; Pizov R
    Eur J Anaesthesiol; 2010 Jul; 27(7):617-23. PubMed ID: 20035230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial.
    Serebruany VL; Malinin AI; Pokov A; Barsness G; Hanley DF
    Am Heart J; 2008 Jan; 155(1):93.e1-7. PubMed ID: 18082496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.
    Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS
    Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of obesity on platelet reactivity and response to low-dose aspirin.
    Bordeaux BC; Qayyum R; Yanek LR; Vaidya D; Becker LC; Faraday N; Becker DM
    Prev Cardiol; 2010; 13(2):56-62. PubMed ID: 20377806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of high platelet reactivity during aspirin treatment in patients with type 2 diabetes.
    Kapłon-Cieślicka A; Rosiak M; Postuła M; Serafin A; Kondracka A; Opolski G; Filipiak KJ
    Kardiol Pol; 2013; 71(9):893-902. PubMed ID: 24065375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin.
    Duzenli MA; Ozdemir K; Aygul N; Soylu A; Tokac M
    Am J Cardiol; 2008 Aug; 102(4):396-400. PubMed ID: 18678294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences.
    Anzellotti P; Capone ML; Jeyam A; Tacconelli S; Bruno A; Tontodonati P; Di Francesco L; Grossi L; Renda G; Merciaro G; Di Gregorio P; Price TS; Garcia Rodriguez LA; Patrignani P
    Arthritis Rheum; 2011 Mar; 63(3):850-9. PubMed ID: 21360514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Platelets; 2011; 22(3):188-95. PubMed ID: 21231857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.